Informatietype:
Project
Unit:
High Tech Industry

CollaneX Therapeutics: working on a breakthrough in the fight against fibrosis

Fibrosis is the excessive formation of connective tissue in an organ or tissue; it is known from scars, but it can also occur in the liver as a result of obesity. An unhealthy lifestyle causes liver fibrosis to increase to such an extent that the disease almost begins to take on epidemic proportions, and no medicine is yet available. TNO has built up unique knowledge over the past decade that it wants to co-develop further with market parties into an effective medicine. This is currently being done by the newly founded CollaneX Therapeutics, a spin-off company of TNO. This biotech company will develop medicines against fibrosis, initially during the first phase of development independently, later in collaboration with pharmaceutical companies.

Working on a breakthrough in the fight against fibrosis

Fibrosis is the excessive formation of connective tissue in an organ or tissue; it is known from scars, but it can also occur in the liver as a result of obesity. An unhealthy lifestyle causes liver fibrosis to increase to such an extent that the disease almost begins to take on epidemic proportions, and no medicine is yet available. TNO has built up unique knowledge over the past decade that it wants to co-develop further with market parties into an effective medicine.
This is currently being done by the newly founded CollaneX Therapeutics, a spin-off company of TNO. This biotech company will develop medicines against fibrosis, initially during the first phase of development independently, later in collaboration with pharmaceutical companies.

Number of patients growing

Efforts to develop anti-fibrosis medicines are happening worldwide. Fibrosis can occur in many organs, such as the heart, lungs, liver and kidneys, and the number of patients with liver fibrosis is rising sharply. In the US alone 130 million people are affected by obesity, which in many cases leads to liver disorders and consequently an increase in the number of liver transplants as a result of fibrosis.

Why from TNO?

As a TNO spin-off, CollaneX has unique knowledge of both the disease and the pharmaceutical market. The scientists forming the company have developed numerous models that provide insight into the mechanisms of the disease as well as identified a unique target that helps to develop a medicine with potentially few side effects. The unique combination of knowledge of mechanisms, models and the market has convinced CollaneX that it can make a breakthrough in the fight against fibrosis.

Get inspired

803 resultaten, getoond 1 t/m 5

GEMINI: intelligent decision support system for geothermal assets

Informatietype:
Insight
30 November 2023
Geothermal energy is regaining momentum as a renewable energy source in the race against climate change, with the realistic promise of much broader applications in the years to come.

Researchers call for Dutch leading role in global methane monitoring

Informatietype:
News
30 November 2023

New facility to develop circular plastics on an industrial scale

Informatietype:
News
28 November 2023

Quantum Application Lab receives grant for quantum computing application development

Informatietype:
News
24 November 2023

TNO helps study effectiveness of Black Blades with sensors, cameras and radar

Informatietype:
News
22 November 2023